AI-Personalized Discharge Education for Patients After Lung Cancer Surgery
About this study
This randomized controlled trial evaluates the effect of artificial intelligence (AI)-personalized discharge education on discharge teaching quality and recovery outcomes in patients after lung cancer surgery. Eligible participants will be randomly assigned in a 1:1 ratio to either an intervention group or a control group. The control group will receive routine discharge education, including verbal instructions and a standardized printed discharge booklet. The intervention group will receive the same routine education plus an AI-generated personalized discharge guidance plan based on individual clinical and care-related information. All AI-generated content will be reviewed by a responsible nurse before being provided to participants. The primary outcome is the quality of discharge teaching measured on the day of discharge. Secondary outcomes include self-efficacy for postoperative rehabilitation management and quality of life assessed one month after discharge.
- Condition
- Lung Cancer (Diagnosis)
- Tested
- AI-Personalized Discharge Education, Routine Discharge Education
- Sponsor
- Xiamen University
Who can join
- Age
- 18 to 80 years
- Sex
- All sexes
- Healthy volunteers
- Not accepted
Inclusion 10
- Minimum age: 18 years
- Maximum age: 80 years
- Study condition: Lung Cancer (Diagnosis)
- Pathologically confirmed primary lung cancer and underwent radical lung cancer surgery by thoracoscopic or open approach, including lobectomy, pneumonectomy, or wedge resection.
- Age 18 to 80 years.
- Clinical stage I to III.
- No distant organ metastasis.
- Clinically stable after surgery, conscious, and able to perform basic listening, speaking, and reading activities, with planned discharge to home for recovery.
- The participant or primary caregiver is able to use a smartphone and WeChat.
- Able and willing to provide informed consent and voluntarily participate in the study.
Exclusion 6
- Recurrent lung cancer or previous treatment with targeted therapy, chemotherapy, or radiotherapy.
- Severe aphasia, cognitive impairment (MMSE \<24), or psychiatric disorders that prevent independent completion of study questionnaires.
- Severe cardiac, hepatic, or renal dysfunction, or another malignant tumor.
- Severe postoperative complications requiring prolonged hospitalization, such as bronchopleural fistula or major bleeding.
- Participation in another interventional clinical study.
- Unable to complete the 1-month follow-up because of travel or residence outside the study area after discharge.
Where
1 site, 1 recruiting
Siping Central People's Hospital
Siping, Jilin, China
Contact
-
Weiguang Zhou, Master's
+86 13624449503 254402969@qq.com
Potential match only. Final eligibility is determined by the study team.